Safety and Efficacy: Clinical Experience of Venetoclax in Combination With Hypomethylating Agents in Both Newly Diagnosed and Relapsed/Refractory Advanced Myeloid Malignancies

by Jonathan Feld, Douglas Tremblay, Mikaela Dougherty, Tina Czaplinska, Gillian Sanchez, Claudia Brady, Marina Kremyanskaya, Michal Bar-Natan, Alla Keyzner, Bridget K. Marcellino, Janice Gabrilove, Shyamala C. Navada, Lewis R. Silverman, Siraj M. El Jamal, John Mascarenhas, Alan H. Shih
Published 2021-04-01